Table 1 Summary of included trials comparing bevacizumab with interferon (Bev + IFN), sunitinib, and pazopanib to interferon alone (IFN) or one another as first-line therapy for patients with clear cell renal cell carcinoma

Rini et al. (2008; 2013) [15, 16]

Bev + IFN^b,c (n = 369)

18.3

0.86 (0.73-1.01)

8.5

0.71 (0.61-0.83)

26%

2.27 (1.51-3.42)

IFN^c (n = 363)

17.4

5.2

13%

Escudier et al. (2007; 2010) [17, 18]

Bev + IFN^b,c (n = 327)

23.3

0.86 (0.72-1.04)

10.2

0.61 (0.51-0.73)

31%^f

3.11 (2.04-4.74)

IFN^c (n = 322)

21.3

5.4

13%^f

Motzer et al. (2013) [19]

Pazopanib^d (n = 557)

28.4

0.91 (0.76-1.08)

8.4

1.05 (0.90-1.22)

31%

1.35 (1.03-1.75)

Sunitinib^e (n = 553)

29.3

9.5

25%

Motzer et al. (2007; 2009) [14]

Sunitinib^e (n = 375)

26.4

0.82 (0.67-1.00)

11

0.54 (0.45-0.64)

47%

6.33 (4.37-9.15)

IFN^c (n = 375)

21.8

5

12%